Secukinumab (AIN457) is a high-affinity monoclonal antibody against interleukin (IL-17A). Secukinumab (AIN457) is a first-in-class anti-IL-17 agent in the study of plaque psoriasis, ankylosing spondylitis, and psoriatic arthritis.
| Molecular Weight | 147941.89 |
| Formula | C6584H10134N1754O2042S44 |
| CAS Number | 875356-43-7 |
| Storage | -80°C for long term |
| Species | Mouse | Rat | Rabbit | Guinea pig | Hamster | Dog |
| Weight (kg) | 0.02 | 0.15 | 1.8 | 0.4 | 0.08 | 10 |
| Body Surface Area (m2) | 0.007 | 0.025 | 0.15 | 0.05 | 0.02 | 0.5 |
| Km factor | 3 | 6 | 12 | 8 | 5 | 20 |
| Animal A (mg/kg) = Animal B (mg/kg) multiplied by | Animal B Km |
| Animal A Km |
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
[1] Kristian Reich, et al. N Engl J Med. Bimekizumab versus Secukinumab in Plaque Psoriasis
[2] Hannah A Blair. Drugs. Secukinumab: A Review in Psoriatic Arthritis
[3] Hannah A Blair. Drugs. Secukinumab: A Review in Ankylosing Spondylitis
| Related IL Receptor/Related Products |
|---|
| 13-Methylberberine chloride
13-Methylberberine chloride is a berberine analogue, has anti-adipogenic and antitumor activities. 13-Methylberberine chloride increases production of IL-12 and inhibits the expression of iNOS at posttranscriptional level in macrophages activated with LPS. |
| HB0017
HB0017 is a monoclonal antibody that targets interleukin-17 (IL-17) and selectively binds IL-17A, thereby preventing IL-1717A from binding to its receptor. |
| Rademikibart
Rademikibart is a human IgG4ҡ monoclonal antibody that targets IL-4 Rα to block inflammatory signaling induced by IL-4 and IL-13, two important cytokines that drive allergic inflammation, and binds to the human IL-4Rα epitope with a KD of 20.7 pM. Rademikibart does not bind to IL-4Rα from other species. Rademikibart does not bind to IL-4Rα of other species.Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation, and TARC production in PBMC, and can be used in studies related to moderate-to-severe Th2 inflammatory diseases. |
| Stapokibart
Stapokibart is a humanized monoclonal antibody targeting IL-4Rα that blocks the interaction of cytokines IL-4 and IL-13 with their co-receptor subunit, IL-4Rα. Stapokibart is able to interact with IL-4Rα in humans, cynomolgus monkeys, and rats, and can be used in atopic dermatitis research. |
| Erepdekinra
Erepdekinra is an interleukin-17A (IL-17A) receptor antagonist. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
